Exactitude Consultancy
Home Report Store Categories Primary Research Consulting Services Blog Contact us About Us Terms & Conditions Privacy Policy
Facebook Twitter Linkedin
+1 (704) 266-3234
Request Free Sample
Home > Life Sciences > Companion Diagnostics Market

Companion Diagnostics Market

Apr 2023

Base Year Value ()

x.x %
x.x %

CAGR ()

x.x %
x.x %

Forecast Year Value ()

x.x %
x.x %

Historical Data Period

Largest Region

Forecast Period

Mercado de diagnósticos complementarios por productos (ensayos, kits y reactivos, software y servicios), por tecnología (reacción en cadena de la polimerasa, secuenciación de próxima generación, hibridación in situ, inmunohistoquímica), por indicación (cáncer, enfermedades neurológicas, enfermedades infecciosas, enfermedades cardiovasculares), por usuario final (empresas farmacéuticas y biofarmacéuticas, organizaciones de investigación por contrato, laboratorios) y región, tendencias globales y pronóstico de 2022 a 2029

Instant access to hundreds of data points and trends

  • Market estimates from 2014-2029
  • Competitive analysis, industry segmentation, financial benchmarks
  • Incorporates SWOT, Porter's Five Forces and risk management frameworks
  • PDF report or online database with Word, Excel and PowerPoint export options
  • 100% money back guarantee
Purchase Options
Download Sample

Descripción general del mercado de diagnóstico complementario


Se espera que el mercado de diagnósticos complementarios crezca a una tasa anual compuesta del 13,34 % entre 2021 y 2029. Se espera que alcance más de 13 230 millones de dólares en 2029 desde los 3500 millones de dólares en 2020.

Los diagnósticos complementarios son pruebas in vitro que brindan información sobre las respuestas terapéuticas de los pacientes a un tratamiento específico. Se trata de un dispositivo médico in vitro que brinda información necesaria para el manejo seguro y eficaz de un medicamento o producto biológico correspondiente. Esta prueba diagnóstica ayuda al médico a determinar si un producto terapéutico específico es beneficioso para los pacientes y puede compensar cualquier posible efecto secundario o riesgo grave.


El aumento de los distintos tipos de cáncer entre las personas es el principal factor que impulsa el crecimiento del mercado. A medida que aumenta el número de ensayos clínicos y la demanda de secuenciación de última generación , también lo hará el mercado de diagnóstico complementario. Otro factor que impulsa dicho crecimiento es la importancia de los productos de este mercado en la producción de diversos tipos de medicamentos.


Se espera que el mercado de diagnósticos complementarios crezca significativamente durante el período de pronóstico, debido a un aumento en la I+D de terapias dirigidas, un aumento en la demanda de medicina de precisión con creciente atención en las economías emergentes, el descubrimiento de nuevos biomarcadores para diversas afecciones y un mayor número de necesidades insatisfechas para el tratamiento del cáncer.


Con los avances en la secuenciación hereditaria y la genómica, ahora se acepta ampliamente que los medicamentos pueden generar resultados variables en diferentes personas. Una mejor comprensión de las características hereditarias o los biomarcadores de un individuo puede hacer avanzar el acto de supervisar "la medicación correcta, en el momento perfecto, en la dosis correcta, para el individuo perfecto". Las compañías farmacéuticas y biofarmacéuticas trabajan constantemente para implementar sistemas analíticos de elección del paciente en las primeras etapas del desarrollo de medicamentos con el fin de proporcionar tratamientos específicos al competidor adecuado. Esto contribuye al crecimiento del mercado de diagnósticos complementarios.


























































ATRIBUTODETALLES
Periodo de estudio2020-2029
Año base2022
Año estimado2022
Año pronosticado2022-2029
Periodo histórico2018-2020
UnidadValor (miles de millones de USD)
SegmentaciónPor oferta, por tecnología, por indicación, por usuario final, por región
Por tecnología de resina

  • Ensayos, kits y reactivos

  • Software y servicios


Por tecnología

 

  • Reacción en cadena de la polimerasa

  • Secuenciación de próxima generación

  • Hibridación in situ

  • Inmunohistoquímica


Por indicación

  • Cáncer

  • Enfermedades neurológicas

  • Enfermedades infecciosas

  • Enfermedades cardiovasculares


Por el usuario final

  • Empresas farmacéuticas y biofarmacéuticas

  • Organizaciones de investigación por contrato

  • Laboratorios


Por región

  • América del norte

  • Asia Pacífico

  • Europa

  • Sudamerica

  • Oriente Medio, Asia y África



La introducción de la COVID-19 ha obstaculizado el consumo de diagnósticos complementarios. Además, los principales actores del mercado sufrieron una caída significativa de los ingresos como resultado de la pandemia de COVID-19, debido a una reducción en el volumen de pruebas y otros factores. En lo que respecta a los ingresos, el mercado creció un 15,1% en 2020, en comparación con el 19,8% en 2019.


Los ingresos generados por los principales actores disminuyeron significativamente en 2020. Por ejemplo, Myriad Genetics, Inc. informó una disminución del 34,5 % en los ingresos por diagnóstico molecular en 2020 en comparación con 2019. Además, Abbott Laboratories informó una disminución del 4,0 % en los ingresos por diagnósticos de laboratorio básicos en 2020 en comparación con 2019.


Sin embargo, el levantamiento de las restricciones de confinamiento, las órdenes de quedarse en casa en muchos países, la introducción de nuevas pruebas de diagnóstico y el restablecimiento de la red de la cadena de suministro fueron factores clave en la recuperación de las pruebas en 2021. Como resultado, la reanudación de las pruebas de diagnóstico del cáncer y la introducción de nuevas pruebas de diagnóstico impulsaron la demanda en 2021.




[título id="attachment_14559" align="aligncenter" width="1024"]Companion Diagnostics Market | Exactitude Consultancy
Mercado de diagnóstico complementario | Exactitude Consultancy
[/subtítulo]

Frequently Asked Questions

• What is the worth of companion diagnostics market?

The companion diagnostics market size had crossed USD 3.5 Billion in 2020 and will observe a CAGR of more than 13.34% up to 2029.

• What are some of the market's driving forces?

Major factors driving the companion diagnostics market growth include the significant growth of companion diagnostics in drug development and rising incidence of cancer and growing adoption of targeted therapies.

• Which are the top companies to hold the market share in companion diagnostics market?

Qiagen, Agilent Technologies, Roche, Abbott Laboratories, Inc., BioMerieux, Ventana Medical Systems, Myriad Genetics, Inc., Resonance Health Ltd, Leica Microsystems, Life Technologies, F. Hoffmann-L Roche Ltd., Illumina, Inc., Guardant Health, Thermo Fisher Scientific Inc., Danaher Corporation are the major companion diagnostics market players.

• Which is the largest regional market for companion diagnostics market?

The region's largest share is in North America. Products manufactured in nations like US and Canada that perform similarly and are inexpensively accessible to the general public have led to the increasing appeal.

Companion Diagnostics Market Segment Analysis

The companion diagnostics market is segmented based on products, technology, indication, end user, and region, global trends and forecast.

On the basis of products, the market is segmented into assays, kits & reagents, software & services. Due to increase in demand for kits and reagents, the assays, kits and reagents segment is estimated to lead.

On the basis of technology, the market is segmented into polymerase chain reaction, next-generation sequencing, in situ hybridization, immunohistochemistry.

Based on technology, the pcr segment currently dominates the global market and is expected to do so throughout the forecast period. Cost effectiveness, high sensitivity, and specificity, which can be used for simple automated platforms, are some key factors driving market growth. Furthermore, the pcr, which is another key driver of this segment, can determine the sequencing of unknown etiologies of many diseases. However, the next generation sequencing segment is expected to grow rapidly during the forecast period due to key advantages such as higher sensitivity to detect low-frequency variants, shorter turnaround time for large sample volumes, the ability to sequence hundreds to thousands of genes or gene regions simultaneously, and so on.

On the basis of indication, the market is segmented into cancer, neurological diseases, infectious diseases, cardiovascular diseases.

The cancer segment is currently the largest revenue generator and is expected to grow significantly during the forecast period. Some key factors driving the growth of the cancer segment include increased cancer prevalence, increased r&d activities for cancer, increased unmet needs for cancer treatment, increased number of fda approved companion diagnostics, and increased patient awareness of personalized medicine.

Cancer research has discovered significant differences in gene sequence and expression patterns that can serve as the foundation for targeted therapy. Furthermore, many biomarkers for various cancers have been identified, for which companion diagnostics have been developed. Companion diagnostics are widely used in various types of cancer, including lung cancer, colorectal cancer, breast cancer, and blood cancer, which are the leading causes of death.

On the basis of end user, the market is segmented into pharmaceutical & biopharmaceutical companies, contract research organizations, laboratories.

There is no denying that contract research organizations (cros) are becoming more important in the development of companion diagnostics. As the demand for personalized medicine grows, cros are uniquely positioned to assist pharmaceutical and biotechnology companies in developing customized treatments based on a patient's unique genetic makeup.

Companion diagnostics are diagnostic tests used to identify patients who are likely to benefit from a specific treatment. They can also be used to track a patient's response to therapy and make necessary adjustments. Cancer, cardiovascular disease, and infectious diseases are just a few of the conditions that can be treated with companion diagnostics.

[caption id="attachment_14563" align="aligncenter" width="1920"]Companion Diagnostics Market | Exactitude Consultancy
Companion Diagnostics Market | Exactitude Consultancy
[/caption]

Companion Diagnostics Market Players

Qiagen, Agilent Technologies, Roche, Abbott Laboratories, Inc., BioMerieux, Ventana Medical Systems, Myriad Genetics, Inc., Resonance Health Ltd, Leica Microsystems, Life Technologies, F. Hoffmann-L Roche Ltd., Illumina, Inc., Guardant Health, Thermo Fisher Scientific Inc., Danaher Corporation are the major Companion Diagnostics market players. Recent Developments: 23 January, 2023: QIAGEN Digital Insights announced launch of their enhanced QIAGEN CLC Genomics Workbench Premium that removes the data-analysis bottleneck of Next-Generation Sequencing by adding analysis speed to analyze and interpret Whole Genome Sequencing, Whole Exome Sequencing and Large Panel Sequencing data. 9 January, 2023: QIAGEN announced of having been completed the acquisition of Verogen, a leader in the use of Next-Generation Sequencing technologies to drive the future of human identification and forensic investigation.

Who Should Buy? Or Key stakeholders

  • Pharmaceutical Companies
  • Research and Development (R&D) Companies
  • Diagnostic Laboratories
  • Government Research Institute
  • Academic Institutes and Universities
  • Investors
  • Regulatory Authorities

Companion Diagnostics Market Regional Analysis

The Companion Diagnostics Market by region includes North America, Asia-Pacific (APAC), Europe, South America, and Middle East & Africa (MEA).

  • North America: includes the US, Canada, Mexico
  • Asia Pacific: includes China, Japan, South Korea, India, Australia, ASEAN and Rest of APAC
  • Europe: includes UK, Germany, France, Italy, Spain, Russia, and Rest of Europe
  • South America: includes Brazil, Argentina and Rest of South America
  • Middle East & Africa: includes Turkey, UAE, Saudi Arabia, South Africa, and Rest of MEA

North America is expected to lead the global companion diagnostics market. This could explain the high incidence rate of cancer and other chronic diseases, as well as the rising cost of healthcare in the area. Furthermore, market development is expected to drive an increase in the number of healthcare organisations working on generated genomic databases to better understand the human genome, as well as increased research activities in this area using companion diagnostic kits.

The European market for companion diagnostics is expected to be the second-largest during the review period. The expansion of the regional industry is expected to fuel the participation of a large number of companies as well as increased research and development activities aimed at improving personalised drug treatment for cancer patients. Furthermore, rising per capita income increases the preference for personalised treatment, fueling further consumer growth.

Because of the rapidly increasing number of cancer, cardiovascular, and neurological patients, Asia-Pacific is expected to be the fastest growing region. Furthermore, the rising prevalence of infectious diseases has a positive impact on business development. The high prevalence of cancer, increasing proteomics and genomics research, rising research funding, increasing investments by pharmaceutical and biotechnology firms, and rising awareness of personalised therapeutics in many APAC countries are expected to drive the growth of the APAC companion diagnostics market.

The Middle East and Africa market is expected to grow steadily due to an increase in cancer cases and a growing preference for customised drugs. The Middle East and Africa market is expected to grow steadily due to an increase in the number of hospitals and research labs, increased investment by healthcare firms, an increase in cancer cases, and increased drug discovery.

[caption id="attachment_14564" align="aligncenter" width="1920"]Companion Diagnostics Market | Exactitude Consultancy
Companion Diagnostics Market | Exactitude Consultancy
[/caption]

Key Market Segments: Companion Diagnostics Market

  • Companion Diagnostics Market By Offering 2020-2029, (Usd Billion)
  • Assays, Kits & Reagents
  • Software & Services
Companion Diagnostics Market By Technology, 2020-2029, (Usd Billion)
  • Polymerase Chain Reaction
  • Next-Generation Sequencing
  • In Situ Hybridization
  • Immunohistochemistry
Companion Diagnostics Market By Indication, 2020-2029, (Usd Billion)
  • Cancer
  • Neurological Diseases
  • Infectious Diseases
  • Cardiovascular Diseases
Companion Diagnostics Market By End User, 2020-2029, (Usd Billion)
  • Pharmaceutical & Biopharmaceutical Companies
  • Contract Research Organizations
  • Laboratories
Companion Diagnostics Market By Region, 2020-2029, (Usd Billion)
  • North America
  • Asia Pacific
  • Europe
  • South America
  • Middle East And Africa
Important Countries In All Regions Are Covered.

Exactitude Consultancy Core Companion Diagnostics Services Key Objectives:

  • Increasing sales and market share
  • Developing new technology
  • Improving profitability
  • Entering new markets
  • Enhancing brand reputation

Key Question Answered

  • What is the expected growth rate of the companion diagnostics market over the next 7 years?
  • Who are the major players in the companion diagnostics market and what is their market share?
  • What are the end-user industries driving demand for market and what is their outlook?
  • What are the opportunities for growth in emerging markets such as Asia-Pacific, Middle East, and Africa?
  • How is the economic environment affecting the companion diagnostics market, including factors such as interest rates, inflation, and exchange rates?
  • What is the expected impact of government policies and regulations on the companion diagnostics market?
  • What is the current and forecasted size and growth rate of the global companion diagnostics market?
  • What are the key drivers of growth in the companion diagnostics market?
  • What are the distribution channels and supply chain dynamics in the companion diagnostics market?
  • What are the technological advancements and innovations in the companion diagnostics market and their impact on product development and growth?
  • What are the regulatory considerations and their impact on the market?
  • What are the challenges faced by players in the companion diagnostics market and how are they addressing these challenges?
  • What are the opportunities for growth and expansion in the companion diagnostics market?
  • What are the service offerings and specifications of leading players in the market?

  1. INTRODUCCIÓN

    1. DEFINICIÓN DE MERCADO

    2. SEGMENTACIÓN DEL MERCADO

    3. CRONOGRAMAS DE INVESTIGACIÓN

    4. SUPUESTOS Y LIMITACIONES



  2. METODOLOGÍA DE LA INVESTIGACIÓN

    1. MINERÍA DE DATOS

      1. INVESTIGACIÓN SECUNDARIA

      2. INVESTIGACIÓN PRIMARIA

      3. ASESORAMIENTO DE EXPERTOS EN LA MATERIA



    2. CONTROLES DE CALIDAD

      1. REVISIÓN FINAL



    3. TRIANGULACIÓN DE DATOS

      1. ENFOQUE DE ABAJO HACIA ARRIBA

      2. ENFOQUE DE ARRIBA HACIA ABAJO

      3. FLUJO DE INVESTIGACIÓN



    4. FUENTES DE DATOS



  3. RESUMEN EJECUTIVO

  4. PANORAMA DEL MERCADO

    1. PERSPECTIVA DEL MERCADO GLOBAL DE DIAGNÓSTICOS COMPLEMENTARIOS

      1. IMPULSORES DEL MERCADO

      2. RESTRICCIONES DEL MERCADO

      3. OPORTUNIDADES DE MERCADO



    2. IMPACTO DEL COVID-19 EN EL MERCADO DE DIAGNÓSTICOS COMPAÑERISMOS

    3. MODELO DE LAS CINCO FUERZAS DE PORTER

      1. AMENAZA DE NUEVOS INGRESANTES

      2. AMENAZA DE SUSTITUTOS

      3. PODER DE NEGOCIACIÓN DE LOS PROVEEDORES

      4. PODER DE NEGOCIACIÓN DE LOS CLIENTES

      5. GRADO DE COMPETENCIA



    4. ANÁLISIS DE LA CADENA DE VALOR DE LA INDUSTRIA



  5. MERCADO GLOBAL DE DIAGNÓSTICOS COMPAÑEROS POR OFERTA (MIL MILLONES DE USD), 2020-2029

    1. ENSAYOS, KITS Y REACTIVOS

    2. SOFTWARE Y SERVICIOS

    3. SERVICIOS BÁSICOS DE DIAGNÓSTICO COMPLEMENTARIO



  6. MERCADO GLOBAL DE DIAGNÓSTICOS COMPLEMENTARIOS POR TECNOLOGÍA (MIL MILLONES DE USD), 2020-2029

    1. REACCIÓN EN CADENA DE LA POLIMERASA

    2. SECUENCIACIÓN DE ÚLTIMA GENERACIÓN

    3. HIBRIDACIÓN IN SITU

    4. INMUNOHISTOQUÍMICA



  7. MERCADO GLOBAL DE DIAGNÓSTICOS COMPLEMENTARIOS POR INDICACIÓN (MIL MILLONES DE USD), 2020-2029

    1. CÁNCER

    2. ENFERMEDADES NEUROLÓGICAS

    3. ENFERMEDADES INFECCIOSAS

    4. ENFERMEDADES CARDIOVASCULARES



  8. GLOBAL COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION), 2020-2029

    1. PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES

    2. CONTRACT RESEARCH ORGANIZATIONS

    3. LABORATORIES



  9. GLOBAL COMPANION DIAGNOSTICS MARKET BY REGION (USD BILLION), 2020-2029

    1. NORTH AMERICA

      1. US

      2. CANADA

      3. MEXICO



    2. SOUTH AMERICA

      1. BRAZIL

      2. ARGENTINA

      3. COLOMBIA

      4. REST OF SOUTH AMERICA



    3. EUROPE

      1. GERMANY

      2. UK

      3. FRANCE

      4. ITALY

      5. SPAIN

      6. RUSSIA

      7. REST OF EUROPE



    4. ASIA PACIFIC

      1. INDIA

      2. CHINA

      3. JAPAN

      4. SOUTH KOREA

      5. AUSTRALIA

      6. SOUTH-EAST ASIA

      7. REST OF ASIA PACIFIC



    5. MIDDLE EAST AND AFRICA

      1. UAE

      2. SAUDI ARABIA

      3. SOUTH AFRICA

      4. REST OF MIDDLE EAST AND AFRICA







  1. COMPANY PROFILES* (BUSINESS OVERVIEW, COMPANY SNAPSHOT, PRODUCT OFFERED, RECENT DEVELOPMENTS)

    1. QIAGEN

    2. AGILENT TECHNOLOGIES

    3. ROCHE

    4. ABBOTT LABORATORIES, INC.

    5. BIOMERIEUX

    6. VENTANA MEDICAL SYSTEMS

    7. MYRIAD GENETICS, INC.

    8. RESONANCE HEALTH LTD

    9. LEICA MICROSYSTEMS

    10. LIFE TECHNOLOGIES

    11. HOFFMANN-LA ROCHE LTD.

    12. ILLUMINA, INC.

    13. GUARDANT HEALTH

    14. THERMO FISHER SCIENTIFIC INC.

    15. DANAHER CORPORATION *THE COMPANY LIST IS INDICATIVE




LIST OF TABLES


TABLE 1        GLOBAL COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 2        GLOBAL COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 3        GLOBAL COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 4        GLOBAL COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 5        GLOBAL COMPANION DIAGNOSTICS MARKET BY REGION (USD BILLION) 2020-2029

TABLE 6        NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY COUNTRY (USD BILLION) 2020-2029

TABLE 7        NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 8        NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 9        NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 10      NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 11      US COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 12      US COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 13      US COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 14      US COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 15      CANADA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 16      CANADA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 17      CANADA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 18      CANADA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 19      MEXICO COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 20      MEXICO COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 21      MEXICO COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 22      MEXICO COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 23      SOUTH AMERICA COMPANION DIAGNOSTICS MARKET BY COUNTRY (USD BILLION) 2020-2029

TABLE 24      SOUTH AMERICA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 25      SOUTH AMERICA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 26      SOUTH AMERICA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 27      SOUTH AMERICA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 28      BRAZIL COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 29      BRAZIL COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 30      BRAZIL COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 31      BRAZIL COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 32      ARGENTINA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 33      ARGENTINA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 34      ARGENTINA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 35      ARGENTINA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 36      COLOMBIA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 37      COLOMBIA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 38      COLOMBIA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 39      COLOMBIA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 40      REST OF SOUTH AMERICA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 41      REST OF SOUTH AMERICA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 42      REST OF SOUTH AMERICA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 43      REST OF SOUTH AMERICA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 44      ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET BY COUNTRY (USD BILLION) 2020-2029

TABLE 45      ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 46      ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 47      ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 48      ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 49      INDIA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 50      INDIA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 51      INDIA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 52      INDIA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 53      CHINA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 54      CHINA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 55      CHINA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 56      CHINA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 57      JAPAN COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 58      JAPAN COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 59      JAPAN COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 60      JAPAN COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 61      SOUTH KOREA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 62      SOUTH KOREA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 63      SOUTH KOREA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 64      SOUTH KOREA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 65      AUSTRALIA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 66      AUSTRALIA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 67      AUSTRALIA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 68      AUSTRALIA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 69      SOUTH-EAST ASIA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 70      SOUTH-EAST ASIA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 71      SOUTH-EAST ASIA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 72      SOUTH-EAST ASIA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 73      REST OF ASIA PACIFIC COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 74      REST OF ASIA PACIFIC COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 75      REST OF ASIA PACIFIC COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 76      REST OF ASIA PACIFIC COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 77      EUROPE COMPANION DIAGNOSTICS MARKET BY COUNTRY (USD BILLION) 2020-2029

TABLE 78      ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 79      ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 80      ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 81      ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 82      GERMANY COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 83      GERMANY COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 84      GERMANY COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 85      GERMANY COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 86      UK COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 87      UK COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 88      UK COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 89      UK COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 90      FRANCE COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 91      FRANCE COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 92      FRANCE COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 93      FRANCE COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 94      ITALY COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 95      ITALY COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 96      ITALY COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 97      ITALY COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 98      SPAIN COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 99      SPAIN COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 100    SPAIN COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 101    SPAIN COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 102    RUSSIA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 103    RUSSIA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 104    RUSSIA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 105    RUSSIA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 106    REST OF EUROPE COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 107    REST OF EUROPE COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 108    REST OF EUROPE COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 109    REST OF EUROPE COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 110    MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET BY COUNTRY (USD BILLION) 2020-2029

TABLE 111    MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 112    MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 113    MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 114    MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 115    UAE COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 116    UAE COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 117    UAE COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 118    UAE COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 119    SAUDI ARABIA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 120    SAUDI ARABIA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 121    SAUDI ARABIA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 122    SAUDI ARABIA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 123    SOUTH AFRICA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 124    SOUTH AFRICA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 125    SOUTH AFRICA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 126    SOUTH AFRICA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 127    REST OF MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029

TABLE 128    REST OF MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029

TABLE 129    REST OF MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029

TABLE 130    REST OF MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029

LIST OF FIGURES


FIGURE 1 MARKET DYNAMICS

FIGURE 2 REPORT TIMELINES: YEARS CONSIDERED

FIGURE 3 BOTTOM-UP APPROACH

FIGURE 4 RESEARCH FLOW

FIGURE 5 GLOBAL COMPANION DIAGNOSTICS MARKET BY OFFERING USD BILLION, 2020-2029

FIGURE 6 GLOBAL COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, USD BILLION, 2020-2029

FIGURE 7 GLOBAL COMPANION DIAGNOSTICS MARKET BY APPLICATION, USD BILLION, 2020-2029

FIGURE 8 GLOBAL COMPANION DIAGNOSTICS MARKET BY END USER, USD BILLION, 2020-2029

FIGURE 9 GLOBAL COMPANION DIAGNOSTICS MARKET BY REGION, USD BILLION, 2020-2029

FIGURE 10 PORTER’S FIVE FORCES MODEL

FIGURE 11 GLOBAL COMPANION DIAGNOSTICS MARKET BY OFFERING, USD BILLION, 2021

FIGURE 12 GLOBAL COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, USD BILLION, 2021

FIGURE 13 GLOBAL COMPANION DIAGNOSTICS MARKET BY APPLICATION, USD BILLION, 2021

FIGURE 14 GLOBAL COMPANION DIAGNOSTICS MARKET BY END USER, USD BILLION, 2021

FIGURE 15 GLOBAL COMPANION DIAGNOSTICS MARKET BY REGION, USD BILLION, 2021

FIGURE 16 MARKET SHARE ANALYSIS

FIGURE 17 QIAGEN: COMPANY SNAPSHOT

FIGURE 18 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT

FIGURE 19 ROCHE: COMPANY SNAPSHOT

FIGURE 20 ABBOTT LABORATORIES, INC.: COMPANY SNAPSHOT

FIGURE 21 BIOMERIEUX: COMPANY SNAPSHOT

FIGURE 22 VENTANA MEDICAL SYSTEMS: COMPANY SNAPSHOT

FIGURE 23 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT

FIGURE 24 RESONANCE HEALTH LTD: COMPANY SNAPSHOT

FIGURE 25 LEICA MICROSYSTEMS: COMPANY SNAPSHOT

FIGURE 26 LIFE TECHNOLOGIES: COMPANY SNAPSHOT

FIGURE 27 F. HOFFMANN-L ROCHE LTD.: COMPANY SNAPSHOT

FIGURE 28 ILLUMINA, INC.: COMPANY SNAPSHOT

FIGURE 29 GUARDANT HEALTH: COMPANY SNAPSHOT

FIGURE 30 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT

FIGURE 31 DANAHER CORPORATION: COMPANY SNAPSHOT

DOWNLOAD FREE SAMPLE REPORT

Kindly share your specific requirement (if any)
2379

License Type

Single User

US$ 3499

Multi User

US$ 4499

Corporate User

US$ 5499
Buy Now
Enquiry Before Buying

Get Sample to Email

SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click To Email +1 (704) 266-3234 +91 7972605446

WANT TO CUSTOMIZE THE REPORT?

Click Here

Our Clients Speak

We asked them to research ‘ Equipment market’ all over the world, and their whole arrangement was helpful to us. thehealthanalytics.com insightful analysis and reports contributed to our current analysis and in creating a future strategy. Besides, the te

Yosuke Mitsui

Senior Associate Construction Equipment Sales & Marketing

We asked them to research ‘Equipment market’ all over the world, and their whole arrangement was helpful to us. thehealthanalytics.com insightful analysis and reports contributed to our current analysis and in creating a future strategy. Besides, the te

Yosuke Mitsui

Senior Associate Construction Equipment Sales & Marketing

Why choose us

Proactive

We manage our resources 24/7 to identify issues and address them before they become problems

Quality & Reliability

We are committed to providing reliable and highly accurate data with an excellent quality control system

Global Outreach

6 Major regions and 40+ countries level analysis accomplished

Competitive Pricing

Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery

In-Depth Database

In-Depth Database

Our Report’s database covers almost all topics of all regions over the Globe.

Recognised Publishing Sources

Recognised Publishing Sources

Tie ups with top publishers around the globe.

Customer Support

Customer Support

Complete pre and post sales support.

Safe & Secure

Safe & Secure

Complete secure payment process.

Talk to Expert

Call for an appointment!

+1 (704) 266-3234

Feel free to message us!

Send an Email

Contact us

ddcde742412eaeabeaf7f82820481462.png
Exactitude Consultancy Plot No. 39, SR, 10-16, NDA Pashan Rd, Bavdhan, Pune, Maharashtra 411021 +1 (704) 266-3234 +91 7972605446 sales@exactitudeconsultancy.com

Quick Links

About Blog Contact Us Sitemap
How to order Delivery Method Return Policy FAQ Privacy Policy Disclaimer Terms and Conditions

We accept

Exactitude Consultancy

2026 © Exactitude Consultancy | All rights reserved

Exactitude Consultancy Email Us
Exactitude Consultancy Contact Us
Exactitude Consultancy +1 (704) 266-3234